from concepts to biomarkers

& innovations in precision medicine

17 research teams,

9 platforms, 3 hosted biotechs

our state-of-the-art tools,

for cancer research

in the heart of a campus dedicated to applied cancer research...

...and Montpellier,

a city historically linked to medical research and teaching

the IRCM research teams
the IRCM research teams

L'Institut de Recherche en Cancérologie de Montpellier :
«Together, let's push the boundaries»

News

SEMINAIRE EXTERNE IRCM

Borhane GUEZGUEZDepartment Hematology and Medical Oncology, University Medical Center Mainz, Germany"Advancing Cancer Therapy in Leukemia : The Intersection of Epigenetics, Inflammation and Tumor Microenvironment"host : Alexandre Djiane (IRCM)
En savoir plus

SEMINAIRE EXTERNE IRCM

Eileen PARKESAssociate Professor,Innate tumor Immunology laboratoryOxford University, England"Targeting immunosuppression in Chromosomally unstable cancers"Dr Eileen Parkes is an early phase medical oncologist and associate professor at the University of Oxford. She completed her medical oncology training and PhD at Queens University Belfast before moving to Oxford in 2019. She leads early phase studies of novel IO, including STING agonsits, and is lead for Oxford Experimental Cancer Medicine Centre, focusing on translational research. Her lab team studies the tumour microenvironment of chromosomally unstable cancers, with a particular focus on cGAS-STING signalling, intending to identify novel therapeutic strategies for chromosomally unstable cancers including oesophageal adenocarcinomas. host: Julien Faget (IRCM)
En savoir plus

Trois doctorants de l'IRCM, David Bracquemont, Marianne Richaud et Pierre Giroux participeront à la Nuit Méditerranéenne des Chercheuses, le 27 septembre prochain.

Trois doctorants de l’IRCM, David Bracquemont, Marianne Richaud et Pierre Giroux participeront à la Nuit Méditerranéenne des Chercheuses, le 27 septembre prochain.
En savoir plus

SEMINAIRE EXTERNE IRCM

Mickaël Le Clech, PhDBusiness DeveloperENSCM-USCBF-CN"Discover your drug candidate with ChemBioFrance and the French National Chemical Library"host : Eric JULIEN (IRCM)
En savoir plus

SEMINAIRE EXTERNE IRCM

Jihane BASBOUS, PhDInstitut de Génétique Humaine (IGH), CNRS UMR 9002Université de Montpellier, France"Compartmentalization of the DNA damage response: Mechanisms and functions"Our research investigates the molecular mechanisms and functions of protein compartmentalization in response to DNA damage and repair. Focusing on two critical scaffolding proteins, TopBP1 and SLX4, we have elucidated how their assembly into nanocondensate clusters following DNA damage activates specific signalling pathways. Our research aims to demonstrate how DNA repair foci, functioning as biomolecular condensates, link molecular mechanisms to cellular physiological functions. Our work offers valuable insights into the regulatory mechanisms of the DNA damage response compartmentalization and opens new avenues for developing innovative cancer management strategies.  
En savoir plus

SEMINAIRE EXTERNE IRCM

Damien GREGOIREInstitut de Génétique Moléculaire de Montpellier (IGMM) CNRS-UMR 5535Route de Mende, Montpellier"Oncogenic cooperations : investigating inter and intra-tumoral heterogeneity in hepatocellular carcinoma"Dr. Gregoire and his collaborators develop innovative murine models to study liver cancer heterogenity. They explore how the genetic composition of hepatocarcinoma influences their development, their interaction with the microenvironment, and their response to therapies.
En savoir plus

SEMINAIRE EXTERNE IRCM

Raphael J. MorscherPediatric Cancer Metabolism Laboratory, Children's Research Center,University of Zurich, 8032 Zurich, Suisse"Reprogramming neuroblastoma translation by diet-enhanced polyamine depletion"hôte : Alexandre DAVID (IRCM)
En savoir plus

SEMINAIRE EXTERNE IRCM

Gilles PAGESUniversité Cote d'Azur,Institut de Recherche Cancer et Vieillissement de Nice (IRCAN)UMR CNRS 7284/U Inserm 1081 "From the discovery of mechanisms of resistance to conventional therapies to the establishment of innovative treatments for metastatic kidney cancers"hôte : Alexandre DAVID (IRCM)
En savoir plus

SEMINAIRE IRCM vendredi 29 Novembre 14h

Bassam Janji, PhDGroup Leader, Tumor Immunotherapy and MicroenvironmentLuxembourg Institute of Health, Department of Cancer Research"Breaking the Shield: Innovative Approaches to Overcome the Immunosuppressive Tumor Microenvironment and Improve Cancer Immunotherapy."contact : Andrei Turtoi (IRCM)
En savoir plus

SEMINAIRE IRCM VENDREDI 04 OCTOBRE 14h

Emmanuelle HUILLARDEquipe "Génétique et développement des tumeurs cérébrales" Institut du Cerveau / ICMHôpital de la Pitié-SalpêtrièreCNRS UMR7225-Inserm U1127-Sorbonne Université"Mechanisms of tumor initiation in IDH-mutant gliomas"contact : Lucille STUANI (IRCM)  
En savoir plus

the word of the director

"Together, let's push the limits."

"In barely 20 years, the Institut de Recherche en Cancérologie de Montpellier (IRCM U1194) has succeeded in raising its research to the highest international level in the field of fundamental and applied cancer research, carried out in close collaboration with the clinical departments of the Montpellier Cancer Center (ICM: l'Institut du Cancer de Montpellier), and industrial partners. Under the joint supervision of Inserm, the ICM and the University of Montpellier, the IRCM brings together more than 240 people, researchers, clinicians, technicians and students, organized in 16 research teams that rely on high-performance technical platforms and competent support services. In an extremely competitive and rapidly evolving field of research, our greatest challenge is to stay one step ahead. To do so, we will continue to structure cancer research in Montpellier, to seek excellence and to accelerate innovation and transfer to the patient in order to ultimately contribute to overcoming the countless different forms of cancer. Together, let's push the limits"

Nathalie Bonnefoy, Director of the IRCM

the word of the director

MAIN PUBLICATIONS

Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol J-L, Calvayrac O, Moll H, Glasson Y, Pirot N, Turtoi A, Cañamero M, Wong K-K, Yarden Y, Casanova E, Soria J-C, Colinge J, Siebel C, Favre G, Paz-Ares L, Maraver A Notch inhibition overcomes resistance to Tyrosine Kinase Inhibitors in EGFR-driven lung adenocarcinoma. J. Clin. Invest.. Oct 31, 2019. doi:10.1172/JCI126896

Combes E, Andrade A, Tosi D, Michaud H-A, Coquel F, Desigaud D, Jarlier M, Coquelle A, Pasero P, Bonnefoy N, Martineau P, Del Rio M, Beijersbergen R, Vezzio-Vie N Inhibition of Ataxia-Telangiectasia Mutated and RAD3-related (ATR) overcomes oxaliplatin resistance and promotes anti-tumor immunity in colorectal cancer. Cancer Res.. Apr 15, 2019. doi:10.1158/0008-5472.CAN-18-2807

Ashraf Y, Mansouri H, Laurent-Matha V, Alcaraz L, Roger P, Guiu S, Derocq D, Robin G, Michaud H-A, Jarlier M, Pugnière M, Robert B, Puel A, Martin L, Landomiel F, Bourquard T, Achour O, Fruitier-Arnaudin I, Pichard A, Deshayes E, Turtoi A, Poupon A, Boissière-Michot F, Pirot N, Bernex F, Jacot W, du Manoir S, Theillet C, Pouget J-P, Navarro-Teulon I, Bonnefoy N, Pèlegrin A, Chardès T, Martineau P, Liaudet-Coopman E Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies. J Immunother Cancer. 2019;7(1):29. doi:10.1186/s40425-019-0498-z

Perrot I, Michaud H-A, Giraudon-Paoli M, Augier S, Docquier A, Gros L, Courtois R, Jecko D, Becquart O, Rispaud-Blanc H, Gauthier L, Rossi B, Chanteux S, Gourdin N, Amigues B, Roussel A, Bensussan A, Eliaou J-F, Bastid J, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E, Paturel C, Bonnefoy N Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies. Cell Rep. 2019;27(8):2411-2425.e9. doi:10.1016/j.celrep.2019.04.091

Forest E, Logeay R, Géminard C, Kantar D, Frayssinoux F, Heron-Milhavet L, Djiane A The apical scaffold big bang binds to spectrins and regulates the growth of Drosophila melanogaster wing discs. J. Cell Biol.. 2018;217(3):1047-1062. doi:10.1083/jcb.201705107

Arena G, Cissé M, Pyrdziak S, Chatre L, Riscal R, Fuentes M, Arnold J, Kastner M, Gayte L, Bertrand-Gaday C, Nay K, Angebault-Prouteau C, Murray K, Chabi B, Koechlin-Ramonatxo C, Orsetti B, Vincent C, Marine J-C, Etienne-Manneville S, Bernex F, Lombès A, Cameron C, Dubouchaud H, Ricchetti M, Linares L, Le Cam L Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53. Mol. Cell. 2018;69(4):594-609.e8. doi:10.1016/j.molcel.2018.01.023

Leconet W, Chentouf M, du Manoir S, Chevalier C, Sirvent A, Aït-Arsa I, Busson M, Jarlier M, Radosevic-Robin N, Theillet C, Chalbos D, Pasquet J-M, Pèlegrin A, Larbouret C, Robert B Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis. Clin. Cancer Res.. 2017;23(11):2806-2816. doi:10.1158/1078-0432.CCR-16-1316

Brustel J, Kirstein N, Izard F, Grimaud C, Prorok P, Cayrou C, Schotta G, Abdelsamie A, Déjardin J, Méchali M, Baldacci G, Sardet C, Cadoret J-C, Schepers A, Julien E Histone H4K20 tri-methylation at late-firing origins ensures timely heterochromatin replication. EMBO J.. 2017;36(18):2726-2741. doi:10.15252/embj.201796541


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés